19171-19-8
Pomalidomide
CAS: 19171-19-8
Molecular Formula: C13H11N3O4
19171-19-8 - Names and Identifiers
| Name | Pomalidomide |
| Synonyms | CC-4047 ActiMid Pomalidomide Pomalidomide(CC-4047) Pomalidomide(CC-4047,Actimid) 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-AMino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione 1H-Isoindole-1,3(2H)-dione,4-aMino-2-(2,6-dioxo-3-piperidinyl)- |
| CAS | 19171-19-8 |
| EINECS | 805-902-5 |
| InChI | InChI=1/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) |
| InChIKey | UVSMNLNDYGZFPF-UHFFFAOYSA-N |
19171-19-8 - Physico-chemical Properties
| Molecular Formula | C13H11N3O4 |
| Molar Mass | 273.24 |
| Density | 1.570±0.06 g/cm3(Predicted) |
| Melting Point | 318.5 - 320.5° |
| Boling Point | 582.9±45.0 °C(Predicted) |
| Flash Point | 306.3°C |
| Solubility | DMSO:54 mg/mL (197.62 mM);Water :Insoluble;Ethanol :Insoluble mother liquor preservation: sub-packaging and freezing to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 |
| Vapor Presure | 1.41E-13mmHg at 25°C |
| Appearance | Light yellow to yellow solid |
| Color | yellow |
| Merck | 14,135 |
| pKa | 10.75±0.40(Predicted) |
| Storage Condition | 2-8°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
| Refractive Index | 1.691 |
| Use | This product is for scientific research only and shall not be used for other purposes. |
| In vitro study | Pomalidomide inhibits lipopolysaccharide (LPS)-stimulated release by TNF-alpha, with IC50 values of 13 nM and 25 nM for human PBMC and total human blood, respectively. Pomalidomide inhibited IL-2 of stimulated T regulatory cells with an IC50 of ~ 1 μm. Treatment of human peripheral blood T cells with 6.4 nM-10 μm Pomalidomide increased production by IL-2 and was more effective on the CD4 + subset than on the CD8 + subset. Pomalidoride significantly promoted IFN-γ by CC-5013, IL-2, and IL-5 over IL-10, and slightly promoted IFN-γ over CC-5013. Pomalidomide acts on Jurkat cells to enhance the AP-1 transcriptional activity induced by SEE and Raji cells, up to 4-fold at 1 μm, in a dose-dependent manner. Treatment of Raji cells with different concentrations of pomalido IDE (2.5-40 μg/mL) for 48 hours resulted in a significant decrease in cell proliferation and DNA synthesis by-40% compared to the control group. |
| In vivo study | Pomalidomide acts on SCID mice to enhance the anticancer effect of Rituximab on B- cell lymphoma. The combination of pomalidoxide and Rituximab resulted in an average life span of 74 days in mice and 58 days in mice treated with CC5013/Rituximab. NK cell depletion completely abolished the synergistic effect of pomalidoride and Rituximab, indicating that the increase in NK cells is a mechanism by which pomalidoride enhances the anticancer effect of Rituximab. |
19171-19-8 - Risk and Safety
| WGK Germany | 3 |
| RTECS | NR3397905 |
| HS Code | 29251900 |
19171-19-8 - Introduction
Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.
Last Update：2022-10-16 17:14:41
19171-19-8 - Reference Information
| introduction | pomalidomide (Pomalidomide) is a newly listed third-generation immunomodulator (Immuno-modulatorydrug,IMiD), developed by Celgene, USA. it is a drug modified and synthesized on the basis of the chemical structure of the first-generation IMiD thalidomide, it can enhance the immune response mediated by T cells and natural killer cells, inhibit the production of pro-inflammatory cytokines of monocytes, and induce tumor cell apoptosis. It has attracted extensive attention in the treatment of various malignant tumors and immune diseases. |
| features | compared with the first and second generation IMiD, pomalidomide is relatively more pharmacological, less toxic and better tolerated by patients. its good anti-angiogenesis, anti-tumor and anti-inflammatory effects have been widely recognized in the pre-clinical studies of multiple myeloma (Multiplemyeloma,MM). |
| Use | The chemical name of pomalidomide is 4-amino-2-(2, 6-dioxo-piperidine-3-yl)-Isodihydroindol-1, 3-dione, is a thalidomide analog, an immunomodulator with anti-tumor activity. In vitro cytology tests, it can inhibit the proliferation of hematopoietic tumor cells and induce apoptosis. In addition, pomalidomide can inhibit the proliferation of lenalidomide-resistant multiple myeloma cell lines and induce tumor cell apoptosis in cooperation with dexamethasone. |
| biological activity | Pomalidomide inhibit LPS-induced TNF-alpha release with IC50 of 13 nM. |
| in vitro study | Pomalidomide inhibit lipopolysaccharide (LPS)-stimulated TNF-alpha release, IC50 is 13 nM and 25 nM respectively when acting on human PBMC and all human blood. Pomalidomide inhibit IL-2-stimulated T regulatory cells, IC50 is ~ 1 μM. 6.4 nM-10 μM Pomalidomide to treat human peripheral blood T cells to increase IL-2 yield. It is more effective on CD4 + subsets than CD8 + subsets. Pomalidomide significantly promotes IL-2, IL-5, and IL-10 than CC-5013, and slightly promotes IFN-γ than CC-5013. Pomalidomide acts on Jurkat cells to enhance the AP-1 transcription activity induced by SEE and Raji cells, with a maximum of 4-fold enhancement at 1 μM. This effect is dose-dependent. Treatment of Raji cells with different concentrations of Pomalidomide(2.5-40 μg/mL) for 48 hours resulted in a significant decrease in cell proliferation and DNA synthesis, which was ~ 40% lower than that of the control group. |
| In vivo studies | Pomalidomide act on SCID mice to enhance the anti-cancer effect of Rituximab on B- cell lymphoma. The average lifespan of rats with Pomalidomide and Rituximab was 74 days, and that of rats treated with CC5013/Rituximab was 58 days. When NK cells are exhausted, the synergistic effect of Pomalidomide and Rituximab is completely abolished, indicating that the increase of NK cells is a mechanism that Pomalidomide enhances Rituximab cancer. |
| feature | Pomalidomide are Thalidomide derivatives, and the effect is 10,000 times stronger than Thalidomide. |
| Preparation | is to use 3-nitrophthalic anhydride as the starting material and react with 3-amino-2, 6-piperidinedione, and the prepared product is reduced by Pd/C in a hydrogen environment to obtain the target compound pomalidomide. Although the steps of the reaction route are short, 3-nitrophthalic anhydride is an unstable raw material, which is easy to hydrolyze and deteriorate during transportation or storage, the quality of the raw material is not guaranteed, and the reaction process is an intermittent reaction system., The degree of continuity is low, hydrogen is a high-risk gas, and the safety of the production environment is low. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 20:45:29
Supplier List
Spot supply
Product Name: Pomalidomide Visit Supplier Webpage Request for quotationCAS: 19171-19-8
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple SpecificationsSpot supply
Product Name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Visit Supplier Webpage Request for quotationCAS: 19171-19-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Pomalidomide Visit Supplier Webpage Request for quotationCAS: 19171-19-8
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple SpecificationsSpot supply
Product Name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Visit Supplier Webpage Request for quotationCAS: 19171-19-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History